Technology areas: Chemistry & Materials • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Bioshare AB currently has 2 pending office actions in the Medical Devices & Mechanical Engineering technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. LAU, JASON is the busiest examiner, managing 1 pending office action.
The distribution of 2 pending office actions across 2 distinct examiners indicates that the company's active cases are being handled independently. This lack of examiner overlap means that the legal team must interact with two different individuals, each with their own examination style. The presence of 2 distinct art units further suggests that the 2 pending office actions involve different technical sub-specialties. Practitioners should be prepared for two separate prosecution tracks, as the influence of LAU, JASON is limited to 1 pending office action. This decentralized structure for a small portfolio requires careful attention to ensure that arguments made to one examiner do not conflict with those made to the other. The involvement of 2 distinct examiners for the 2 pending office actions highlights the need for individualized attention to each application's unique requirements.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LAU, JASON | 1 | 54.1% | +15.9% |
| CHANDLER, KAITY V | 1 | 64.4% | +22.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18519022 | Bubbling Fluidized Bed Reactor | CHANDLER, KAITY V | 27d |
| 18728865 | Continuous Char Separation Reactor | LAU, JASON | — |
| Art Unit | Apps |
|---|---|
| 3762 | 1 |
| 1725 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18728865 | Continuous Char Separation Reactor | LAU, JASON | 3762 | §103 | Non-Final OA | — | Pending | Jul 13, 2024 |
| 18519022 | Bubbling Fluidized Bed Reactor | CHANDLER, KAITY V | 1725 | §103DP | Final Rejection | 27d | Pending | Nov 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBioshare AB has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Jason Lau has the most, with 1 of Bioshare AB's pending office actions.
Mostly Medical Devices & Mechanical Engineering (USPTO Tech Center 3700), based on where its pending office actions are examined.